宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

已收盘 05-20 16:08:03

3.570

-0.100

-2.72%

最高3.740	最低3.520	成交量83.38万
今开3.700	昨收3.670	日振幅5.99%
总市值15.42亿	流通市值15.01亿	总股本4.32亿
成交额301.03万	换手率0.20%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":3.57,"timestamp":1779264483003,"preClose":3.67,"halted":0,"volume":833800,"delay":0,"changeRate":-0.02724795640326978,"floatShares":420477305,"shares":432000000,"eps":-0.6098987881209217,"marketStatus":"已收盘","change":-0.1,"latestTime":"05-20 16:08:03","open":3.7,"high":3.74,"low":3.52,"amount":3010262,"amplitude":0.059946,"askPrice":3.6,"askSize":5400,"bidPrice":3.57,"bidSize":5400,"shortable":3,"etf":0,"ttmEps":-0.6455721134638436,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779327000000},"marketStatusCode":5,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":3.67,"openAndCloseTimeList":[[1779240600000,1779249600000],[1779253200000,1779264000000]],"volumeRatio":0.564936,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"2636528108","title":"宜明昂科-B(01541)：IMM0306治疗SLE的II期随机及安慰剂对照试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636528108","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636528108?lang=zh_cn&edition=full","pubTime":"2026-05-19 22:05","pubTimestamp":1779199512,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，IMM0306治疗系统性红斑狼疮 (SLE)的II期随机及安慰剂对照试验顺利完成首例患者给药。预期将招募约90例患者，并按1：1：1的比例随机分配至三个治疗组，分别接受IMM0306(剂量为1.2 mg/kg及1.6 mg/kg)或安慰剂的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","SLE","BK1161","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636835313","title":"宜明昂科-B(01541.HK)尾盘涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636835313","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636835313?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:31","pubTimestamp":1779175900,"startTime":"0","endTime":"0","summary":"5月19日，宜明昂科-B(01541.HK)尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741895653.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741895653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636833670","title":"港股异动 | 宜明昂科-B(01541)尾盘涨超6% IMM0306原发性干燥综合征IND申请正式获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2636833670","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636833670?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:26","pubTimestamp":1779175568,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B尾盘涨超6%，截至发稿，涨5.41%，报3.7港元，成交额231.26万港元。消息面上，宜明昂科近日宣布，公司自主研发的阿沐瑞芙普α，在原发性干燥综合征适应症的新药临床试验申请已正式获得中国国家药品监督管理局批准。这一进展标志着宜明昂科在自身免疫性疾病领域的创新药物研发版图再次迎来重要突破。此次pSS适应症IND的获批，是宜明昂科“自免管线全面推进”战略的又一重要成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK4588","BK4585","BK1161","VXUS","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635749711","title":"宜明昂科-B(01541.HK)获董事长田文志增持5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635749711","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635749711?lang=zh_cn&edition=full","pubTime":"2026-05-14 23:37","pubTimestamp":1778773026,"startTime":"0","endTime":"0","summary":"格隆汇5月14日丨根据联交所最新权益披露资料显示，2026年5月13日，宜明昂科-B(01541.HK)获董事长、首席执行官兼执行董事田文志在场内以每股均价3.87港元增持5万股，涉资约19.35万港元。\r\n\r\n　　增持后，田文志最新持股数目为116,184,090股，持股比例由26.91%上升至27.63%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/14/20260514288847.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/14/20260514288847.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260514/32225341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107596032","title":"宜明昂科-B4月无新增股份发行，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1107596032","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107596032?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:46","pubTimestamp":1778150775,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年5月7日发布2026年4月股份变动月报。报告显示，公司在2026年4月期间，无新增股份发行、回购、注销或库藏等变动活动，股本整体保持稳定。月报并显示，公司已符合香港联合交易所有限公司相关上市规则所要求的公众持股量规定。公司同时确认，将继续遵守香港联交所《上市规则》及相关法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183634513","title":"宜明昂科-B授予董事股份购回授权，规模最高达已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183634513","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183634513?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:56","pubTimestamp":1777539414,"startTime":"0","endTime":"0","summary":"宜明昂科-B公布股东周年大会通告，董事会建议授予股份购回的一般性授权，最多可回购公司已发行股份总数的10%。截至公司公告日，宜明昂科-B已发行股份总数为431,507,695股，如获股东批准，回购上限约为43,150,769股。本次回购资金将来自公司合规的内部资源，董事会认为此举有助于维护公司价值和股东权益，符合公司以及股东的整体最佳利益。过去十二个月内，宜明昂科-B于联交所的H股最高及最低交易价格分别为每股16.80港元和3.43港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B授予董事股份购回授权，规模最高达已发行股本10%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197342960","title":"宜明昂科生物医药技术（上海）股份有限公司2025年收入翻番，研发投入保持高位","url":"https://stock-news.laohu8.com/highlight/detail?id=1197342960","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197342960?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:20","pubTimestamp":1777414810,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2025年12月31日止年度在肿瘤免疫治疗与相关创新药领域持续深耕，“Drug-by-Design”技术平台推进了多款管线的临床试验与适应症拓展。公司管理层表示，研发与临床成果正助力企业于血液肿瘤、实体瘤及部分自身免疫疾病等多个适应症加速布局。公司现金及现金等价物截至年底达到约6.80亿元人民币，为后续研发和营运提供了更为充足的流动性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科生物医药技术（上海）股份有限公司2025年收入翻番，研发投入保持高位","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629097539","title":"港股异动 | 宜明昂科-B(01541)涨超5% 子公司宜明凯尔已完成IMC-003项目MAD研究全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2629097539","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629097539?lang=zh_cn&edition=full","pubTime":"2026-04-22 14:47","pubTimestamp":1776840465,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72项目，针对肺动脉高压适应症的健康人群的多次给药剂量递增研究，已顺利完成全部受试者入组。据介绍，与现有同类药物相比，IMC-003具有独特的差异化特性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","01541","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127356025","title":"异动解读 | 宜明昂科-B盘中大涨11.52%，研发进展与管线拓展获市场看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1127356025","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127356025?lang=zh_cn&edition=full","pubTime":"2026-04-14 10:16","pubTimestamp":1776133003,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中股价大幅上涨11.52%，引起了市场的高度关注。消息面上，公司近期的研发进展与管线拓展是推动股价上涨的主要因素。有市场分析报告指出，公司作为一家以科研为导向的生物技术公司，拥有丰富的创新候选药物管线，上述进展增强了市场对其长期发展潜力的信心，并给出了积极的目标价评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627483659","title":"港股宜明昂科-B大涨超17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627483659","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627483659?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:28","pubTimestamp":1776047320,"startTime":"0","endTime":"0","summary":"4月13日，宜明昂科-B(01541.HK)大涨超17%，截至发稿，涨17.09%，报5.55港元，成交额1143.79万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702619637.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702619637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","VXUS","BK4588","01541","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627488250","title":"港股异动 | 宜明昂科-B(01541)大涨超17% CD47双抗临床价值获《科学》杂志佐证","url":"https://stock-news.laohu8.com/highlight/detail?id=2627488250","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627488250?lang=zh_cn&edition=full","pubTime":"2026-04-13 10:21","pubTimestamp":1776046919,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B大涨超17%，截至发稿，涨17.09%，报5.55港元，成交额1143.79万港元。消息面上，医药魔方文章指出，近日《科学》杂志的论文与宜明昂科在靶点药物开发道路上的思路不谋而合。IMM0306的临床数据有力地证明了：只要药物设计得当，能够同时解决“抗原沉没”的低疗效问题并提供“双信号”的协同激活，CD47靶点依然具有巨大的临床开发价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","01541","BK1161","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161373017","title":"宜明昂科-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1161373017","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161373017?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:11","pubTimestamp":1775643064,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年4月8日发布2026年3月股份变动月报表。报告期内，公司注册股本未发生增减变动，股本结构保持稳定。截至2026年3月31日，注册股本总额约人民币4.32亿元。报告期内，未发生股份新增发行、购回、注销或庫藏股变动，也无期权及股权激励计划调整事项。公告显示，公司确认满足香港联交所的最低公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102540356","title":"异动解读 | 宜明昂科-B盘中大涨5.15%，III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1102540356","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102540356?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:02","pubTimestamp":1774922528,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中股价大幅上涨5.15%，引起了市场的广泛关注。消息面上，公司发布公告称，其独立研发的IMM0306联合来那度胺治疗复发性╱难治性滤泡性淋巴瘤的III期临床试验，已顺利完成首例患者给药。根据公告，IMM0306通过独特的机制阻断“别吃我”信号，激活免疫细胞以消除恶性B细胞，同时旨在降低毒性，改善治疗效果。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623347904","title":"宜明昂科-B(01541)：IMM0306治疗复发性╱难治性滤泡性淋巴瘤的III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2623347904","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623347904?lang=zh_cn&edition=full","pubTime":"2026-03-31 00:28","pubTimestamp":1774888085,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM0306联合来那度胺治疗复发性╱难治性滤泡性淋巴瘤的III期临床试验顺利完成首例患者给药。由本集团独立研发的IMM0306是一种靶向分化簇47 及分化簇20 的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。截至本公告日期，本集团拥有IMM0306的全球知识产权及商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1161","01541","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622072960","title":"宜明昂科-B(01541)发布年度业绩，收入1.54亿元 同比增加108.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072960","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622072960?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:21","pubTimestamp":1774448474,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布截至2025年12月31日止年度业绩，该公司取得收入人民币1.54亿元，同比增加108.09%;本公司股东应占年内亏损人民币2.19亿元，同比收窄30.8%;毛利人民币1.53亿元，同比增加106.59%;每股亏损人民币0.53元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621742594","title":"宜明昂科-B(01541)成功完成IMM01(替达派西普)用于慢性粒-单核细胞白血病(CMML)一线治疗的III期临床试验中期分析的133例患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=2621742594","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621742594?lang=zh_cn&edition=full","pubTime":"2026-03-23 07:22","pubTimestamp":1774221759,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，本公司成功完成IMM01用于慢性粒-单核细胞白血病一线治疗的III期临床试验中期分析的133例患者招募。此外，IMM01的CD47结合结构域经过特别改造能够避免与人体红细胞结合。凭藉差异化的分子设计，IMM01表现出良好的安全性并证实其激活巨噬细胞的能力。IMM01联合阿扎胞苷进行CMML一线治疗于2023年11月获美国食品药品监督管理局授予的孤儿药资格认定。本集团拥有IMM01的全球知识产权及商业化权利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","III","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620283973","title":"港股异动 | 宜明昂科-B(01541)涨超10% IMM0306治疗原发性膜性肾病II期临床获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620283973","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620283973?lang=zh_cn&edition=full","pubTime":"2026-03-18 10:48","pubTimestamp":1773802081,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B涨超10%，截至发稿，涨10.46%，报5.28港元，成交额703.34万港元。消息面上，3月17日，宜明昂科宣布，公司自主研发的阿沐瑞芙普α治疗原发性膜性肾病的II期临床研究已正式获得国家药品监督管理局批准。公司表示，此次IMM0306在治疗原发性膜性肾病适应症上的II期临床获批，连同近期阿沐瑞芙普α皮下注射制剂，是宜明昂科在自身免疫性疾病领域密集布局的最新成果，也是公司“自免管线多点突破”战略的重要体现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","01541","BK1161","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618402919","title":"每日卖空追踪 | 宜明昂科-B 03月11日卖空量成交8.26万股，卖空比例为4.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618402919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618402919?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217822,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间03月11日，涨6.97%，卖空量成交8.26万股，较上一交易日减少41.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163245a6b793fa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163245a6b793fa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618265940","title":"宜明昂科-B盘中异动 股价大涨5.18%报5.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618265940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618265940?lang=zh_cn&edition=full","pubTime":"2026-03-11 10:08","pubTimestamp":1773194894,"startTime":"0","endTime":"0","summary":"2026年03月11日早盘10时08分，宜明昂科-B股票出现波动，股价急速拉升5.18%。截至发稿，该股报5.280港元/股，成交量36.34万股，换手率0.09%，振幅4.98%。资金方面，该股资金流入94.761万港元，流出62.7388万港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为1.20%。其相关个股中，中慧生物-B、加科思-B、创胜集团-B涨幅较大，振幅较大的相关个股有中慧生物-B、科济药业-B、映恩生物-B，振幅分别为18.33%、9.06%、8.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311100814a45fdbd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311100814a45fdbd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618987763","title":"宜明昂科-B盘中异动 股价大涨5.21%报5.050港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987763","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618987763?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:52","pubTimestamp":1773107533,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时52分，宜明昂科-B股票出现波动，股价快速上涨5.21%。截至发稿，该股报5.050港元/股，成交量60.26万股，换手率0.14%，振幅7.71%。资金方面，该股资金流入159.012万港元，流出111.204万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。宜明昂科-B股票所在的生物技术行业中，整体涨幅为4.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031009521397ab79aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031009521397ab79aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.0468},{"period":"1month","weight":-0.3822},{"period":"3month","weight":-0.1934},{"period":"6month","weight":-0.4966},{"period":"1year","weight":-0.4697},{"period":"ytd","weight":-0.3705}],"compareEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0139},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0015},{"period":"1year","weight":0.1057},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}